ArticleResearch and reports in urology2026
Safety of Single-Dose Oral Cefaclor Prophylaxis in Transperineal Prostate Biopsy.
Article in Research and reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Transperineal prostate biopsy is essential for diagnosing prostate cancer; however, infection remains a clinically significant issue. We evaluated the safety and outcome of a single, prophylactic oral dose of cefaclor 500mg during transperineal prostate biopsy. Patients and Methods: This retrospective observational study included 127 patients who underwent transperineal prostate biopsy for suspected prostate cancer at our institution between April 2024 and October 2025. Biopsies were performed transperineally under spinal anesthesia. Cefaclor 500 mg was administered orally 30 minutes pre-operatively as a prophylactic antibiotic. We collected information on laboratory data, medication history, comorbidities, frailty, and infection risk for analysis. Results: Among 127 patients, 73 (57.8%) were classified as prefrail or frail and 27 (21.2%) were identified as at risk of infection. The median initial prostate-specific antigen level was 9.92 ng/mL (interquartile range, 6.55-17.3 ng/mL). Fifty patients (39.3%) with polypharmacy and seventy-one (55.9%) with multimorbidity were noted. All patients were discharged after a 2-day hospital stay. Complications were observed in 36 patients (28.3%). Grade 1 and grade 2 Clavien-Dindo complications occurred in 33 patients (25.9%) and 3 patients (2.3%; urinary retention in 2 patients, fever in 1), respectively. One patient (0.7%) developed a urinary tract infection and underwent additional oral antibiotic therapy. No cases of rehospitalization or sepsis occurred. Among patients who underwent biopsy, 90 (70.8%) tested positive for cancer. Conclusion: Single-dose oral cefaclor prophylaxis in TPB appears to be safe, with no serious post-procedural infections observed. Its effectiveness in frail or high-risk patients requires confirmation in future large prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.